FIVE catalysts that will move this stock
1)positive earnings
2)new licensee
3)insider buying
4)company is bought out
5)pulished data in a well regarded medical journal
I personally feel that insider buying reflects good things to come and it would make me feel much better to see all those that have failed to deliver finally put some skin in the game. It is unfair that everyone at Biocurex has nothing monetarily to lose (potential earnings lost is bullsheet).
This re-launch IMO is peculiar. There is no update anywhere on the collection of new data they make reference to in the pr, so what and where is this new information on the data that requires a relaunch and will drive new sales?
I have been negative for quite some time which may seem counterintuitive to my investment and being a large shareholder, but why can't Dr Moro or Burger close a deal. IMO it has the appearance of him being too greedy or uncreative in his negotiations. There are endless ways to close a deal, but someone there is either unconvincing or just poor at negotiations. If they came to Biocurex they were interested and either Berger or Moro LET THEM WALK. How is this ever going to become the company Dr Moro and Dr Burger speaks of if they let their potential licensees walk away from the table? I just hope their inability to close a deal will end before some new technology comes along, they run out of money, or the patents expire. We must see one of those 5 catalysts I mentioned, otherwise we are going nowhere. The market conditions are absolutely no longer an excuse. Can someone from Biocurex please follow up on the press release as to why he feels he must relaunch oncopet. What was the new data?
